Evidence map›Paper›PMID 30979848›Full record

ArticleThe Journal of biological chemistry2019

Weaponizing T-cell receptors through molecular engineering.

Elissa K Leonard, Michael I Leff, Jamie B Spangler

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Elissa K LeonardFrom the Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland 21218.
Michael I LeffDepartment of Molecular and Cell Biology, Johns Hopkins University, Baltimore, Maryland 21218.
Jamie B SpanglerFrom the Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland 21218; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218. Electronic address: jamie.spangler@jhu.edu.
Johns Hopkins University · US

Funding

ASPIRE - A Joint Johns Hopkins, Morgan State and Coppin State IRACDA ProgramK12GM123914 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BROWN, LISA D., SARMA, SRIDEVI V. · 2018 to 2022
$2.5M
NIGMS NIH HHS K12 GM123914
6 · The paper itself

Abstract

T-cell receptors (TCRs) recognize pathogens to ignite immune responses, making them attractive scaffolds for development as immunotherapeutics. However, manipulation of TCRs has been impeded by difficulties in their engineering and expression. Wagner and colleagues now establish new platforms to generate high-affinity TCR variants that potently activate T cells, and they also create soluble TCR fusion proteins that specifically recognize cognate peptides. This work provides specific tools to combat cytomegalovirus (CMV) infection and helps illuminate a general path to actuation of engineered TCR-based therapeutics.

Indexed as

Gene ExpressionProtein EngineeringAnimalsHumansReceptors, Antigen, T-CellSolubilityReceptors, Antigen, T-Cell

Identifiers

PMID30979848
PMCPMC6463730
OpenAlexW2937989194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.